What is the clinical evidence from this study?

Study design: Meta-Analysis. Population: Acute Myocardial Infarction (STEMI and NSTEMI) (n=344). Intervention: Tocilizumab vs. Placebo. Primary outcome: Recurrent myocardial infarction (RR 0.47, 95% CI 0.07-3.05, p=0.43).

What question did this study set out to answer?

This review aims to explore the effects of interleukin-6 inhibition using tocilizumab in patients with acute myocardial infarction.

June 16, 2026Open Access

Interleukin-6 Inhibition for Patients with Acute Myocardial Infarction: A Systematic Review and Meta-Analysis

Key Result

Tocilizumab did not significantly reduce the risk of recurrent myocardial infarction compared to placebo in patients with acute myocardial infarction (RR 0.47; 95% CI 0.07-3.05; p=0.43).

Key Points

This review aims to explore the effects of interleukin-6 inhibition using tocilizumab in patients with acute myocardial infarction.
Conducted a systematic review following PRISMA guidelines, registered in PROSPERO.
Analyzed three randomized controlled trials involving 344 patients with ST-elevation or non ST-elevation myocardial infarction.
Evaluated outcomes such as infarct size, inflammatory markers, and major adverse cardiovascular events.
Pooled analysis showed no significant difference in recurrent myocardial infarction between tocilizumab and placebo (RR=0.47, 95% CI=0.07–3.05; p=0.43).
No significant difference was observed for infection rates (RR=0.85, 95% CI: 0.29–2.53; p=0.77).
Tocilizumab resulted in lower c-reactive protein levels and transient reductions in NT-proBNP and troponin release, indicating a modulation of inflammatory pathways.

Study Design

Type

Meta-Analysis (n=344)

Structured PICO

Does interleukin-6 inhibition with tocilizumab reduce recurrent myocardial infarction and improve biomarkers in patients with acute myocardial infarction?

Population

344 patients with STEMI or NSTEMI across 3 randomized controlled trials evaluating tocilizumab versus placebo.

Intervention

Interleukin-6 (IL-6) pathway blockade using tocilizumab

Comparator

Placebo

Outcome

Recurrent myocardial infarctionhard clinical

Tocilizumab demonstrates early anti-inflammatory and cardioprotective biomarker effects in acute myocardial infarction, but does not significantly reduce recurrent myocardial infarction or mortality based on current small trials.

Main Result

Relative Risk: 0.47 (95% CI 0.07–3.05)

p-value: p=0.43

Limitations

Need for larger, long-term trials to confirm efficacy and safety

Abstract

Objective: To explore the outcomes associated with interleukin-6 (IL-6) pathway blockade, using tocilizumab, in patients with ST-elevation myocardial infarction (STEMI) and non (NSTEMI). Acute myocardial infarction (AMI) denotes myocardial necrosis due to ischemia and presents in distinct electrocardiographic phenotypes. Inflammation driven by IL-6 contributes to ischemia-reperfusion injury, with tocilizumab showing promise in reducing myocardial damage and improving outcomes. Methods: This work followed the Preferred Reporting Items for Systematic Reviews and Meta-Analysis Framework and was registered in international prospective register of systematic reviews (PROSPERO). Relevant studies were identified through structured searches of PubMed, MEDLINE, the Cochrane Library, and Google Scholar up to June 2025, focusing on randomized and prospective investigations of IL-6 inhibition in AMI. Assessed outcomes included infarct size, inflammatory and cardiac biomarkers, major adverse cardiovascular events, and mortality. Results: Three randomized controlled trials including 344 patients were analyzed. All evaluated tocilizumab in STEMI or NSTEMI. Pooled data showed no significant difference between tocilizumab and placebo for recurrent myocardial infarction (relative risk RR = 0.47, 95% confidence limit CI = 0.07–3.05; I2 = 44%; p = 0.43) or infection (RR = 0.85, 95% CI: 0.29–2.53; I2 = 0%; p = 0.77). Mechanistic analysis demonstrated lower c-reactive protein (CRP) exposure, transient N-terminal pro-B-type natriuretic peptide (NT-proßNP) reductions, and attenuated troponin release in tocilizumab groups, indicating biological modulation of inflammatory and myocardial injury pathways during the acute phase. Benefits were greatest during hospitalization but diminished over time. Long-term outcomes, including ventricular remodeling, NT-proßNP at 6 months, and mortality, showed no significant group differences. Conclusion: The IL-6 inhibition with tocilizumab demonstrates early anti-inflammatory and cardioprotective effects in AMI, but consistent clinical benefits remain unproven, underscoring the need for larger, long-term trials to confirm efficacy and safety.